Q&A with Schenk AccuRate's Chad Lorensen - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Schenk AccuRate's Chad Lorensen
Lorensen discusses client demands and industry trends.

Pharmaceutical Technology
Volume 34, Issue 5, pp. 86

Q & A with
Chad Lorensen, pharmaceutical industry business-development manager of Schenck AccuRate



PharmTech:
What is the biggest industry challenge you're now facing?

Lorensen
The development of continuous manufacturing processes. We are monitoring, helping where we can, and working with companies in the pharmaceutical industry who are studying continuous manufacturing processes for solid dosage products. Our core products have the strengths that provide value for this type of manufacturing process.

PharmTech:
How do you stay abreast of new developments in the industry?

Lorensen
Schenck stays abreast of the latest industry developments through regular communication with our customers, developing strong working relationships with other pharmaceutical-industry equipment manufacturers, and by participating in research consortiums at various universities. Further information is gathered by reviewing various pharmaceutical periodicals and attending trade show exhibitions. In addition, Schenck is a global company, and each of its offices can share ideas with other Schenck locations throughout the world.

PharmTech:
Do you see a new industry trend emerging?

Lorensen
We are looking forward to the pharmaceutical industry's acceptance of continuous mixing, granulation, and hot-melt extrusion.

PharmTech:
What is the most common demand your clients are currently making of you?

Lorensen
The most common request is to provide equipment to customers' sites for trials and experiments made in conjunction with other types of continuous processing equipment.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here